The largest database of trusted experimental protocols

Cd34 progenitor cell isolation kit

Manufactured by Miltenyi Biotec
Sourced in Germany, United States

The CD34 Progenitor Cell Isolation Kit is a lab equipment product designed for the isolation of CD34+ hematopoietic progenitor cells from various sample types. The kit utilizes magnetic bead-based separation technology to selectively capture and enrich CD34+ cells.

Automatically generated - may contain errors

14 protocols using cd34 progenitor cell isolation kit

1

Isolation and Culture of CD34+ Progenitor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Normal CD34 + progenitor cells were enriched with the CD34 + Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch-Gladbach, Germany) from cord blood after full-term deliveries, donated after informed consent. CD34 + cells were maintained in StemSpan SFEM medium supplemented with 20% FCS and StemSpan CC100 (Stemcell Technologies, Vancouver, Canada). K562 and U937 cells were from German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and cultured in RPMI-1640 with 10% FCS.
+ Open protocol
+ Expand
2

Isolation of Hematopoietic Progenitor Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cord blood (CB) and patients' APL samples were obtained after written informed consent was provided in accordance with the Declaration of Helsinki and with approval from the Tokai University Committee on Clinical Investigation (Permit number: #12I-46 and #12I-49). CD34 positive and negative specimens were primarily prepared using the CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD34+ cells were then purified again using anti-human CD34 mAbs (Beckman Coulter, Brea, CA), in combination with or without an anti-CD38 antibody (BD, Franklin Lakes, NJ), with a FACS vantage instrument (BD). CD34/CD33+ cells were also purified again using anti-human CD34 and CD33 mAbs (Beckman Coulter) and the FACS vantage instrument. The preparation of common myeloid progenitors (CMP), granulocyte-monocytic progenitors (GMP) and megakaryocyte-erythrocyte progenitors (MEP) was performed using an anti-CD123 antibody (BD) and anti-CD45RA (Biolegend, San Diego, CA) antibody, according to a previous report [20] (link).
+ Open protocol
+ Expand
3

Hematopoietic Colony Formation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
On day 10 after co-culture, 5 × 104 cells of CD34+ hematopoietic cells were counted for the hematopoietic colony formation units (CFUs) assays by a direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotech, Germany). The cells were resuspended in 100 µL IMDM (Gibco, US) and 10% fetal bovine serum (FBS, HyClone, USA) added with 1-mL per dish of Metho Cult GF + H4435 semisolid medium (Stem cell Technologies, Canada) following the manufacturer’s instructions (Monroe, USA). Fourteen days later, erythroid colonies (Es) were counted and CFU-Es were collected to identify red blood cells. The level of β-globin protein was determined by flow cytometry (BD FACS Arial II, USA). PE Mouse Anti-Human CD71 (Cat.No.555537) was used to identify erythrocyte, and HBB antibody (Santa Cruz Biotechnology, sc-21757) was used to determine the level of β-globin.
+ Open protocol
+ Expand
4

Cell Lines and Primary Samples for T-cell Leukemia and Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
T-cell leukemia (MOLT-4) and lymphoma (HuT 78) cell lines were purchased from the Cell Resource Center of Shanghai Institute for Biological Sciences (Shanghai, China). Bortezomib-resistant MOLT-4 and HuT 78 were obtained by selecting sensitive cells in the presence of nanomolar levels of bortezomib. All cell lines were cultured in RPMI-1640 media (Invitrogen, Frederick, MD), supplemented with 10% fetal bovine serum (FBS), 1% penicillin (100 units/ml), and 1% streptomycin (100 μg/ ml). Cells were maintained at 37°C in an atmosphere of 5% CO2 and 95% air. After informed consent in accordance with the Helsinki Declaration, patient leukemia cells were isolated from the bone marrow of three T-cell leukemia patients and lymphoma cells were obtained from the lymphoma node of one T-cell lymphoma patients. Normal T-lymphocytes were isolated from human peripheral blood using a Pan T Cell Isolation Kit II (Miltenyi Biotec Inc., CA, USA). CD34+ cells were isolated from human peripheral stem cell collection products or human cord blood using CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec Inc., CA, USA). These studies have been approved by the institutional review board of Shanghai Tenth People's Hospital.
+ Open protocol
+ Expand
5

Isolation and culture of ALL cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cord blood Lin-CD34+ precursor cells were isolated using the CD34 Progenitor Cell Isolation Kit Miltenyi Biotech, followed by a negative selection to eliminate Lin+ cells.
The ALL cell lines were obtained from DSMZ (German collections of Microorganisms and Cell Culture) REH (ACC-22) and NALM6 (ACC128) both are B-cell precursor leukemia. The cell lines were maintained at a density of 1×106 cells/mL in RPMI-1640 (GIBCO) in 10% FBS with antibiotics.
+ Open protocol
+ Expand
6

Differentiation of Cord Blood CD34+ Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human cord blood CD34 + cells were separated from human cord blood mononuclear cells (Stemcyte, Covina, CA) by a CD34 + progenitor cell isolation kit (Miltenyi Biotec, North Rhine-Westphalia, Germany). Human cord blood-derived MCs were induced from cord blood CD34 + cells as described previously [16 (link)].
+ Open protocol
+ Expand
7

Isolation of Human CD34+ Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
The study was approved by the ethics evaluation committee of INSERM, institutional review board (IRB00003888) of the French institute of medical research and health (IORG0003254 FWA00005831). CB cells were obtained from Saint-Louis Hospital (Paris, France). mPB cells were collected from the residual cells in bags prepared for transplantation at Pitié Salpêtrière Hospital (Paris, France). Adult bone marrow cells were obtained from hip operations at the “Centre Hospitalier Intercommunal” (Créteil, France). The mononuclear cell fractions were isolated by gradient separation, and human CD34+ cells were isolated with the CD34+ progenitor cell isolation kit (Miltenyi Biotech, Paris, France) and the autoMACSPro instrument (Miltenyi Biotec).
+ Open protocol
+ Expand
8

Isolation and CRISPR/Cas9 Editing of CD34+ Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells were isolated from blood samples after Pancoll fractionation (PAN Biotech). CD34+ cells were then isolated by a magnetic sorting system (Miltenyi Biotec CD34 Progenitor cell isolation kit) following the supplier protocol. CD34+ cells were placed in an in vitro two-phase liquid culture system, as previously described.10 (link) For detailed protocols please refer to the Online Supplementary Appendix.
For cultures treated with pomalidomide, cells were incubated with 1 mM pomalidomide (Sigma) as previously described,11 (link) starting from day 1 (D1) of phase II of culture. For γ-globin derepression experiments using CRISPR/Cas9, patient CD34+ cells were immunoselected and cultured for 48 hours (h) and then electroporated with ribonucleoprotein (RNP) complexes containing Cas9-GFP protein (4.5 mM) and the -197 guide RNA (gRNA) targeting both HBG1 and HBG2 γ-globin promoters (5’ ATTGAGATAGTGTGGGGAAGGGG 3’; protospacer adjacent motif in bold) or a gRNA targeting the Adeno-associated virus integration site 1 (AAVS1; 5’ GGGGCCACTAGGGACAGGATTGG 3’; protospacer adjacent motif in bold).12 (link) Cleavage efficiency was evaluated in cells harvested 6 days after electroporation by Sanger sequencing followed by tracking of indels by decomposition (TIDE) analysis.13 (link)
+ Open protocol
+ Expand
9

Isolation and Transplantation of Umbilical Cord Blood Hematopoietic Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Fresh human umbilical cord blood was obtained from Tongji Hospital, according to guidelines approved by the ethics boards and the Clinical Research Committee at Tongji Hospital. The hematopoietic stem cells (HSCs) were isolated as previously described.26 (link) Briefly, umbilical cord blood mononuclear cells were separated via Ficoll-Hypaque density gradients. CD34+ HSCs were isolated by using a direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec). More than 95% of the CD34+ cells were positively selected after two rounds of enrichment. The HSCs were transplanted within 24 h after isolation.
+ Open protocol
+ Expand
10

Isolation and Culture of Hematopoietic Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
K562, U937, and 293T/17 cells (DSZM, German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) were maintained in RPMI-1640 (K562, U937) or DMEM (293T/17) cell culture medium (Gibco Ltd., Paisley, United Kingdom) supplemented with 10% fetal calf serum (Gibco Ltd.). Cell lines were not passaged for more than 6 months. Umbilical cord blood after full-term deliveries was donated after informed consent, and mononuclear cells were isolated using Lymphoprep (Nycomed Pharma, Oslo, Norway), followed by enrichment of CD34+ cells with the CD34+ Progenitor Cell Isolation Kit (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer's recommendations. CD34+ cells were maintained in StemSpan SFEM medium supplemented with 20% fetal calf serum and StemSpan™ CC100 (Stemcell Technologies, Vancouver, Canada).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!